PresentationGood morning, everyone. Welcome to the Zenas Biopharma Conference Call. [Operator Instructions] Be advised that this call is being recorded at the company's request, and a replay will be available in the Investors section of the company's website following the call.Jennifer FoxChief Business Officer & CFO Thank you, operator, and thank you all for joining us to discuss the top line results of our registrational Phase III INDIGO trial for obexelimab for the treatment of immunoglobulin G4-related ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 5, 2 ...

Key Takeaways ZBIO shares plunged 51.9% on Jan. 5, even after its phase III INDIGO study met the primary endpoint.Obexelimab cut IgG4-RD flare risk by 56% vs. placebo over 52 weeks and met key secondary endpoints.ZBIO plans FDA BLA filing for obexelimab in Q2 2026 and an EMA application in 2H 2026 for IgG4-RD.Zenas BioPharma (ZBIO) announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has me ...

U.S. stock futures were mixed this morning, with the Dow futures falling 0.2% on Tuesday.Shares of Jefferson Capital Inc (NASDAQ:JCAP) fell sharply in pre-market trading after the company lower after the company announced a secondary offering of 10 million shares.Jefferson Capital shares dipped 4.4% to $22.00 in pre-market trading.Here are some other stocks moving lower in pre-market trading.MOBIX LABS, INC. (NASDAQ:MOBX) fell 25.4% to $0.24 in pre-market trading as the company announced plans to launch a c ...

Zenas BioPharma (NASDAQ:ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD).While the trial demonstrated a meaningful reduction in flare risk, efficacy metrics fell short of market expectations, triggering a sharp repricing in the stock. However, when viewed through the Adhishthana framework, this decline appears far from surprising. The stock's cyclical positioning had already signal ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

核心观点 - 市场分析关注三大跌幅最大公司的股价显著波动及其财务健康与市场表现 [1] - 这些公司的价格剧烈变动突显了股市尤其生物科技和科技板块的波动性 [4] - 临床实验结果、监管决策和竞争压力是影响这些板块股价的关键因素 [5] Zenas BioPharma Inc. (ZBIO) 分析 - 股价大幅下跌57.30%至14.73美元，源于其obexelimab药物三期INDIGO试验结果公布后的市场负面反应 [1] - 尽管试验结果积极，但市场反应出乎意料地负面，体现了生物科技投资的不确定性 [1][5] - 该公司领跌榜单，凸显了生物科技板块的波动性 [5] Signing Day Sports, Inc. (SGN) 分析 - 股价下跌46.30%至0.51美元 [2] - 公司运营体育招聘平台，近期宣布了与BlockchAIn Digital Infrastructure在AI和HPC基础设施方面的合作机会 [2] - 竞争压力和运营挑战可能是导致其股价下跌的因素 [2] Shineco, Inc. (SISI) 分析 - 股价下跌37.16%至0.18美元 [3] - 这家北京纺织品公司在盘中交易时段下跌6.8%，尽管交易量减少了99% [3] - 市场认为中国相关行业的市场竞争和监管挑战可能影响了其表现 [3]

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 250 points on Monday.The Dow traded up 1.66% to 49,183.51 while the NASDAQ gained 0.80% to 23,420.85. The S&P 500 also rose, gaining, 0.81% to 6,913.76.Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend YieldsLeading and Lagging SectorsEnergy shares gained by 2.9% on Monday.In trading on Monday, utilities stocks dipped by 2.2%.Top HeadlineThe ISM manufactur ...

Zenas BioPharma Inc. (NASDAQ:ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).IgG4-RD is an immune system disorder where the body creates excess IgG4 antibodies, leading to inflammation and dense, tumor-like tissue growths (fibrosis) in multiple organs. Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of I ...

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday.Following the market opening Monday, the Dow traded up 0.54% to 48,641.58 while the NASDAQ gained 0.65% to 23,386.57. The S&P 500 also rose, gaining, 0.63% to 6,901.52.Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend YieldsLeading and Lagging SectorsEnergy shares gained by 2.9% on Monday.In trading on Monday, consumer staples stocks dipped by 0.4% ...